arrow
D

Drew Dudgeon

Regeneron
H指数:9
被引数:688

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo

基于全人源T细胞受体模拟抗体的CAR T细胞在体内表现出强大的抗肿瘤活性。

2025-03-260
PRE
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Ra strengthens T cell-mediated anti-tumor therapies
2024-10-010
OAAI
REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
2023-12-010
PRE
A PD-1-targeted, receptor-masked IL-2 immunocytokine with maintained potential to engage endogenous IL-2Ra drives selective stimulation of PD-1+ T cells and robust anti-tumor efficacy
2023-04-041
PRE
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

通过CD3亲和力调节产生具有细胞因子释放和生物分布的分化特征的T细胞重定向双特异性抗体

2021-07-1364
OAAI
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
2020-06-2466
PREAI
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

一类增强CD3-bispecific抗体抗肿瘤活性的共刺激CD28-bispecific抗体

2020-01-0894
OAAI
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

开发治疗非人类灵长类动物晚期埃博拉病毒疾病的临床阶段人类单克隆抗体

2018-05-31144
OAAI